FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Glaxo flu vaccine sales pegged at $2.1B

Tools

As the swine flu gathers pace around the world, analysts forecast windfall orders for GlaxoSmithKline's H1N1 vaccine, which they expect to generate at least $2.1 billion in sales next year. Report


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FiercePharma Email Newsletter:

More stories about GlaxoSmithKline   pharmaceutical sales and marketing   swine flu   H1N1